Federal regulators have granted expedited approval to Eli Lilly’s new weight-loss pill, Foundayo, establishing it as the second daily oral medication for obesity and related conditions.
The drug, orforglipron, is a GLP-1 medication. It mimics a natural hormone controlling appetite and fullness, similar to widely used injectable treatments. Shipments of Foundayo are set to begin this Monday.